PT  - JOURNAL ARTICLE
AU  - Lee, Diana
AU  - Avena, Laura E.
AU  - Berrueta, Daniela Montes
AU  - Koch, Matthew
AU  - Choi, Angela
AU  - Oestreicher, Judy
AU  - Hillebrand, William
AU  - Zhou, Honghong
AU  - Pajon, Rolando
AU  - Carfi, Andrea
AU  - Edwards, Darin
AU  - Wu, Kai
TI  - Serum Neutralizing Activity of mRNA-1273 Against the SARS-CoV-2 B.1.1.529 (Omicron) Variant: A Preliminary Report
AID  - 10.1101/2022.01.28.21268247
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.01.28.21268247
4099  - http://medrxiv.org/content/early/2022/01/30/2022.01.28.21268247.short
4100  - http://medrxiv.org/content/early/2022/01/30/2022.01.28.21268247.full
AB  - The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.1.529 (Omicron) variant has led to growing concerns of increased transmissibility and escape of both natural and vaccine-induced immunity. In this analysis, sera from adult participants in a phase 2 clinical study (NCT04405076) were tested for neutralizing activity against B.1.1.529 after a 2-dose (100 µg) mRNA-1273 primary vaccination series and after a 50-µg mRNA-1273 booster dose. Results from this preliminary analysis show that 1 month after completing the primary series, mRNA-1273-elicited serum neutralization of B.1.1.529 was below the lower limit of quantification; however, neutralization was observed at 2 weeks after the mRNA-1273 booster dose, although at a reduced level relative to wild-type SARS-CoV-2 (D614G) and lower than that observed against D614G at 1 month after the primary series.Competing Interest StatementAll authors are employees of Moderna Inc., and hold stock/stock options from the company.Funding StatementThis research was supported by Moderna Inc., and Biomedical Advanced Research and Development Authority, Department of Health and Human Services (contract 75A50120C00034).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participants provided informed consent and all study materials were approved by a central institutional review board (Advarra; Columbia, Maryland); the study was conducted in accordance with the International Council on Harmonization of Good Clinical Practice guidelines.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors declare all data supporting the findings of this analysis are available within this article.